Welcome to our dedicated page for Sophia Genetics Sa SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SOPHiA GENETICS SA (Nasdaq: SOPH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. SOPHiA GENETICS files reports such as Form 20-F and Form 6-K with the U.S. Securities and Exchange Commission, offering detailed information on its financial condition, operations, and material announcements related to its AI-powered healthcare technology business.
Recent Form 6-K filings have included unaudited interim condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and press releases covering quarterly results and business updates. These documents give investors insight into revenue trends, non-IFRS measures such as adjusted gross profit and adjusted EBITDA, geographic revenue breakdowns, and segment information that includes the SOPHiA DDM™ Platform and workflow equipment and services.
Through this page, users can review how SOPHiA GENETICS reports on topics such as platform usage, analysis volumes, regional performance, and capital structure. Filings may also reference warrant liabilities, credit agreements, and other financial instruments, along with discussions of constant currency revenue and other metrics used by management to evaluate performance.
Stock Titan enhances these filings with AI-powered summaries that explain key points in accessible language, helping readers understand complex sections of financial statements and management commentary. Users can quickly identify important themes in SOPHiA GENETICS’ 20-F annual reports, 6-K current reports, and other submissions, and then drill into the original documents for more detail.
In addition, this page offers convenient access to information relevant to governance and capital markets activity, such as exhibits attached to 6-Ks and references to registration statements. While SOPHiA GENETICS is not a U.S. domestic issuer and does not file Forms 10-K or 10-Q, its 20-F and 6-K filings serve a similar role for investors analyzing SOPH stock and the company’s AI-driven precision medicine platform.
SOPHiA GENETICS SA Chief People Officer Manuela Valente sold 380 ordinary shares in an open-market transaction. The shares were sold at a weighted average price of $5.2031 per share on April 20, 2026, and she held 215,071 shares afterward.
According to the disclosure, the sale was made solely to cover tax withholding obligations tied to restricted stock units that vested on April 18, 2026. The transactions were executed under a pre-established Rule 10b5-1(c) trading plan, meaning they were pre-planned and not discretionary market-timing trades.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported an open-market sale of 608 Ordinary Shares at a weighted average price of $5.2053 per share. According to the disclosure, the shares were sold to satisfy tax withholding obligations tied to restricted stock units that vested on April 18, 2026.
The transactions were executed under a pre-established Rule 10b5-1(c) trading plan and are described as non-discretionary. Following these sales, Xu directly holds 630,888 Ordinary Shares.
SOPHiA GENETICS SA Chief Legal Officer Van Well Daan sold 684 Ordinary Shares in an open-market transaction at a weighted average price of $5.1963 per share. The sale occurred on April 20, 2026 and was executed to cover tax withholding obligations from restricted stock units that vested on April 18, 2026.
The filing states that these transactions were carried out under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. After the sale, Van Well Daan directly owned 345,736 Ordinary Shares.
SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported an open-market sale of 4,486 Ordinary Shares. The shares were sold on April 20, 2026 at a weighted average price of $5.205 per share, in multiple trades ranging from $5.08 to $5.29.
The sale was made to satisfy tax withholding obligations arising from restricted stock units that vested on April 18, 2026, under a pre-established Rule 10b5-1(c) trading plan and is described as non-discretionary. After the transaction, Camblong directly holds 3,642,481 Ordinary Shares.
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported a small open-market sale of 608 ordinary shares of SOPH. The shares were sold at a weighted average price of $5.2002 per share and were made to satisfy tax withholding obligations tied to restricted stock units that vested on April 18, 2026.
These transactions were executed under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. After the sale, Menu directly holds 266,388 ordinary shares, indicating that the transaction affected only a very small portion of his overall position.
SOPHiA GENETICS SA President Ross Muken sold 760 Ordinary Shares in an open-market transaction. The shares were sold at a weighted average price of $5.2039 per share to cover tax withholding obligations from restricted stock units that vested on April 18, 2026.
The filing states these sales were made under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. After this tax-related sale, Muken directly holds 681,672 Ordinary Shares, indicating the transaction is small relative to his reported position.
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported a small, non-discretionary share sale tied to taxes. On April 18, 2026, 33 Ordinary Shares were sold in the open market at an average price of $5.0816 per share to satisfy tax obligations from vesting restricted stock units. After this sell-to-cover transaction, he directly holds 148,197 Ordinary Shares.
SOPH insider reported proposed and completed stock sales under a Form 144 and 10b5-1 plan. The filing lists Restricted Stock Units granted with entries of 608 shares (04/18/2026) and 10,000 shares (01/03/2025). Multiple 10b5-1 sales are shown, including 5,000-share trades on 03/12/2026 and 02/12/2026, and smaller sales across February–April 2026.
Jurgi Camblong reported multiple planned sales of Common Stock under a Rule 10b5-1 plan. The filing lists discrete 10b5-1 sale transactions across 2026 (example: 37,299 shares on 01/22/2026 for $209,917.83) and shows Restricted Stock Units (4,486) and Founders Shares (8,500) referenced.
SOPH (Form 144) reports a notice to sell 380 restricted stock units of Common Stock dated 04/18/2026. The filing also lists multiple Rule 10b5-1 open-market sales by Manuela Valente totaling several transactions in Feb–Apr 2026, with individual sell amounts and gross proceeds reported.